全部照片(1)
About This Item
經驗公式（希爾表示法）:
C41H76N2O15
CAS號碼:
分子量：:
837.05
MDL號碼:
分類程式碼代碼:
51282308
PubChem物質ID:
NACRES:
NA.85
推薦產品
化驗
95.0-102.0% (HPLC)
形狀
powder or crystals
溶解度
chloroform: soluble 10 mg/mL
抗生素活性譜
Gram-negative bacteria
Gram-positive bacteria
作用方式
protein synthesis | interferes
儲存溫度
2-8°C
SMILES 字串
CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC3OC(C)CC(C3O)N(C)C)C(C)(O)CC(C)C(=N/OCOCCOC)\C(C)C(O)C1(C)O
InChI
1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+
InChI 密鑰
RXZBMPWDPOLZGW-FEMONOMJSA-N
尋找類似的產品？ 前往 產品比較指南
一般說明
Chemical structure: macrolide
應用
Roxithromycin is a semi-synthetic macrolide antibiotic. Roxithromycin is used to block bacterial protein synthesis. Clinically, it is used to treat respiratory tract, urinary and soft tissue infections. It has a similar antimicrobial spectrum as erythromycin, but is the preferred treatment for certain gram-negative bacteria, such as Legionella pneumophila.
生化／生理作用
Roxithromycin impairs NADPH oxidase activation and alters translocation of its cytosolic components to the neutrophil membrane. It is similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, and clarithromycin. Roxithromycin binds to the subunit 50S of the bacterial ribosome, inhibiting the translocation of peptides.
Semisynthetic erythromycin derivative. Impairs NADPH oxidase activation and alters translocation of its cytosolic components to the neutrophil membrane.
包裝
1g,10g
其他說明
Keep container tightly closed in a dry and well-ventilated place.
訊號詞
Warning
危險聲明
危險分類
Acute Tox. 4 Oral
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
dust mask type N95 (US), Eyeshields, Gloves
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
客戶也查看了
Patorn Piromchai et al.
The Cochrane database of systematic reviews, (5)(5), CD008233-CD008233 (2011-05-13)
Chronic rhinosinusitis (CRS) is a common health problem which significantly affects quality of life. A wide range of medical and surgical therapies have been used to treat CRS. Both systemic and topical antibiotics are used with the aim of eliminating
K Adrjanowicz et al.
Molecular pharmaceutics, 9(6), 1748-1763 (2012-05-01)
Antibiotics are chemical compounds of extremely important medical role. Their history can be traced back more than one hundred years. Despite the passing time and significant progress made in pharmacy and medicine, treatment of many bacterial infections without antibiotics would
X Wang et al.
Journal of veterinary pharmacology and therapeutics, 35(3), 282-289 (2011-07-14)
Tulathromycin is a macrolide antimicrobial agent proposed for therapeutic use in treatment of porcine and bovine respiratory disease. In this study, the absolute bioavailability of tulathromycin solution was investigated in pigs. Eight pigs, with body weight of 20.5 ± 1.6
Z Samra et al.
Journal of chemotherapy (Florence, Italy), 23(2), 77-79 (2011-05-17)
The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution
Nikola Marjanović et al.
Pharmacological research, 63(5), 389-397 (2011-02-15)
Macrolide antibiotics are known to exert anti-inflammatory actions in vivo, including certain effects in COPD patients. In order to investigate the immunomodulatory profile of activity of macrolide antibiotics, we have studied the effects of azithromycin, clarithromycin, erythromycin and roxithromycin on
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務